January 10th 2024
The oral TRT study plans to enroll 20 male patients aged 18 to 49 years who meet the American Urological Association’s criteria for hypogonadism and who have not previously used TRT.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
'Field effect' markers may detect occult prostate Ca
February 25th 2013Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
FDA grants priority review to metastatic PCa agent
February 19th 2013The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.
PDE-5 inhibitor may improve ejaculatory function
February 11th 2013New data suggest the phosphodiesterase type-5 inhibitor tadalafil (Cialis) may be beneficial in helping men who have problems with ejaculation and orgasm, report researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center, New York.
Study questions botulinum’s efficacy in post-BPH overactive bladder
December 31st 2012Intradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.
Minimally invasive RPLND safe, efficacious in testis cancer
December 31st 2012Minimally invasive retroperitoneal lymph node dissection in testicular cancer reduces length of stay while obtaining a perioperative safety profile comparable to that seen with the open procedure, researchers from the University of California, San Diego Health System reported.